adjuvant pembrolizumab after nephrectomy in RCC

adjuvant pembrolizumab after nephrectomy

1. Original Article Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Toni K. Choueiri, M.D., Piotr Tomczak, M.D., Ph.D., Se Hoon Park, M.D., Balaji Venugopal, M.D., Thomas Ferguson, M.D., Yen-Hwa Chang, M.D., Ph.D., Jaroslav Hajek, M.U.Dr., Stefan N. Symeonides, M.D., Ph.D., Jae Lyun Lee, M.D., Ph.D., Naveed Sarwar, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Marine Gross-Goupil, M.D., Ph.D., Mauricio Mahave, M.D., Naomi B. Haas, M.D., Piotr Sawrycki, M.D., Howard Gurney, M.B., B.S., Christine Chevreau, M.D., Bohuslav Melichar, M.D., Ph.D., Evgeniy Kopyltsov, M.D., Ajjai Alva, M.D., John M. Burke, M.D., Gurjyot Doshi, M.D., Delphine Topart, M.D., Stephane Oudard, M.D., Ph.D., Hans Hammers, M.D., Ph.D., Hiroshi Kitamura, M.D., Ph.D., Jens Bedke, M.D., Rodolfo F. Perini, M.D., Pingye Zhang, Ph.D., Kentaro Imai, M.D., Jaqueline Willemann-Rogerio, M.D., David I. Quinn, M.D., Ph.D., Thomas Powles, M.D., for the KEYNOTE-564 Investigators N Engl J Med Volume 385(8):683-694 August 19, 2021

2. Study Overview In a double-blind, randomized trial involving nearly 1000 patients followed for a median of 2 years, pembrolizumab injections for 1 year after surgery led to improved disease-free survival at 24 months as compared with placebo (77% vs. 68%). Almost one third of patients in the pembrolizumab group had a grade 3 adverse event, but no deaths were due to pembrolizumab.

3. Choueiri TK et al. N Engl J Med 2021;385:683-694

4. Disease-free Survival (Intention-to-Treat Population). Choueiri TK et al. N Engl J Med 2021;385:683-694

5. Overall Survival (Intention-to-Treat Population). Choueiri TK et al. N Engl J Med 2021;385:683-694

6. Characteristics of the Patients at Baseline (Intention-to-Treat Population). Choueiri TK et al. N Engl J Med 2021;385:683-694

7. Any-Cause and Treatment-Related Adverse Events (As-Treated Population). Choueiri TK et al. N Engl J Med 2021;385:683-694

8. Any-Cause Adverse Events with an Incidence of at Least 10% in Either Group (As-Treated Population). Choueiri TK et al. N Engl J Med 2021;385:683-694

9. Conclusions Pembrolizumab treatment led to a significant improvement in disease-free survival as compared with placebo after surgery among patients with kidney cancer who were at high risk for recurrence.